175 related articles for article (PubMed ID: 25028605)
1. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
Gentile I; Borgia G
Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
[No Abstract] [Full Text] [Related]
2. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
3. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
[TBL] [Abstract][Full Text] [Related]
6. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
[TBL] [Abstract][Full Text] [Related]
8. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
Graf Einsiedel H; Christiansen H; Wiegand J
Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
[No Abstract] [Full Text] [Related]
9. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Naggie S; Cooper C; Saag M; Workowski K; Ruane P; Towner WJ; Marks K; Luetkemeyer A; Baden RP; Sax PE; Gane E; Santana-Bagur J; Stamm LM; Yang JC; German P; Dvory-Sobol H; Ni L; Pang PS; McHutchison JG; Stedman CA; Morales-Ramirez JO; Bräu N; Jayaweera D; Colson AE; Tebas P; Wong DK; Dieterich D; Sulkowski M;
N Engl J Med; 2015 Aug; 373(8):705-13. PubMed ID: 26196665
[TBL] [Abstract][Full Text] [Related]
10. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
[No Abstract] [Full Text] [Related]
11. Shorter treatments for hepatitis C: another step forward?
Foster GR
Lancet; 2015 Mar; 385(9973):1054-5. PubMed ID: 25591504
[No Abstract] [Full Text] [Related]
12. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
Tapper EB; Bacon BR; Curry MP; Dieterich DT; Flamm SL; Guest LE; Kowdley KV; Lee Y; Tsai NC; Younossi ZM; Afdhal NH
J Viral Hepat; 2017 Jan; 24(1):22-27. PubMed ID: 27730717
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Smith MA; Chan J; Mohammad RA
Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
[TBL] [Abstract][Full Text] [Related]
14. Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
Øvrehus ALH; Krarup H; Birkemose I; Holm DK; Mössner B; Ernst A; Christensen PB
J Hepatol; 2018 Apr; 68(4):840-842. PubMed ID: 29223370
[No Abstract] [Full Text] [Related]
15. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
Elfeki MA; Abou Mrad R; Modaresi Esfeh J; Zein NN; Eghtesad B; Zervos X; Hanouneh IA; O'Shea R; Carey WD; Alkhouri N
Transplantation; 2017 May; 101(5):996-1000. PubMed ID: 27631598
[TBL] [Abstract][Full Text] [Related]
16. Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
Sawinski D; Lee DH; Doyle AM; Blumberg EA
Transplantation; 2017 May; 101(5):974-979. PubMed ID: 27467534
[TBL] [Abstract][Full Text] [Related]
17. Anti-HCV for porphyria cutanea tarda.
Abdelmaksoud A
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133909
[No Abstract] [Full Text] [Related]
18. [Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
Kwon JH
Korean J Gastroenterol; 2015 Aug; 66(2):131-3. PubMed ID: 26513826
[No Abstract] [Full Text] [Related]
19. Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection.
Fouad HM; Sabry MA; Ahmed A; Hassany M; Al Soda MF; Abdel Aziz H
J Pediatric Infect Dis Soc; 2020 Jul; 9(3):386-389. PubMed ID: 31310312
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
